United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 90,567 shares of the biotechnology company's stock after selling 8,761 shares during the period. Los Angeles Capital Management LLC owned 0.20% of United Therapeutics worth $32,455,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of UTHR. Janney Montgomery Scott LLC lifted its position in United Therapeutics by 2.3% in the first quarter. Janney Montgomery Scott LLC now owns 8,960 shares of the biotechnology company's stock worth $2,058,000 after buying an additional 201 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of United Therapeutics by 176.2% during the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company's stock worth $3,288,000 after purchasing an additional 9,133 shares during the period. Oppenheimer & Co. Inc. grew its holdings in United Therapeutics by 17.7% during the 1st quarter. Oppenheimer & Co. Inc. now owns 4,640 shares of the biotechnology company's stock valued at $1,066,000 after purchasing an additional 699 shares during the last quarter. Forsta AP Fonden raised its position in United Therapeutics by 14.5% in the 1st quarter. Forsta AP Fonden now owns 8,700 shares of the biotechnology company's stock worth $1,999,000 after purchasing an additional 1,100 shares during the period. Finally, Sei Investments Co. lifted its stake in United Therapeutics by 3.2% in the first quarter. Sei Investments Co. now owns 37,257 shares of the biotechnology company's stock worth $8,562,000 after purchasing an additional 1,149 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. TD Cowen upped their target price on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, October 21st. The Goldman Sachs Group increased their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Finally, Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $370.86.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the company's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the business's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $344.18, for a total value of $1,239,048.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company's stock, valued at approximately $44,743.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 96,422 shares of company stock valued at $35,251,428 in the last three months. 11.90% of the stock is owned by insiders.

United Therapeutics Stock Performance

UTHR traded down $9.56 during trading on Monday, hitting $400.44. The stock had a trading volume of 445,749 shares, compared to its average volume of 464,781. The stock has a 50 day simple moving average of $359.94 and a two-hundred day simple moving average of $324.54. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The company has a market capitalization of $17.88 billion, a PE ratio of 17.59, a PEG ratio of 1.20 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the previous year, the business earned $5.38 EPS. On average, equities research analysts anticipate that United Therapeutics Co. will post 25.1 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.